An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically-acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation-induced cancers.本發明提供丙啶磺醯胺類化合物及其使用方法,具體涉及如式I所示的新的具有異檸檬酸脫氫酶1(IDH1)抑制活性的化合物或其藥學上可接受的鹽、溶劑化物或水合物、其藥物組合物。本發明還涉及所述化合物或其藥學上可接受的鹽、溶劑化物或水合物和其藥物組合物在治療IDH1突變誘發的癌症中的用途。